The Medical Community Is Discovering The Benefits

The Medical Community Is Discovering The Benefits

Well recognized organizations such as The Associations of American Physicians American Society for Clinical Investigation and the American Federation for Clinical Research recently published the following in a paper presented at the Biomedicine Conference in early May 1996:

"Antigen specific transfer factor is often shown to be highly effective in viral infections unresponsive to prescription medications; and preliminary studies with AIDS patients and HIV-infected macaques have produced encouraging results (18)."

It is clear that transfer factors have many advantages – most notably is its ability to precisely mirror the immune sufficiency of the donor. Yet there remains the proverbial question of economics. Thus far transfer factors have been extremely expensive to research and produce even in very small quantities. It would take a fully staffed laboratory of MD's PhD's and technicians dedicated exclusively to production of transfer factors to make even a small quantity of usable material. The cost per dose would exclude all but the wealthiest people from receiving transfer factors treatment.

Currently due to the generosity of the French government Dr Dimitri Viza in Paris has produced products that contain transfer factors and distributed it to people in various parts of the world. Yet to secure even a small amount thousands of dollars must be paid in advance. This scenario has greatly limited efforts toward mass production of these products until very recently. Fortunately the problems of mass production and administering proper dosages have been addressed and successfully overcome by Dr's Greg Wilson and Gary Paddock (19-23). Their technology now allows transfer factors to be successfully developed using a non-human source. Through strictly controlled replication techniques the "tailored" transfer factors are mass produced which in turn greatly reduces the cost of raw materials by as much as twenty times. Thanks to this new process dosages that contain transfer factors are in the same price range as high-priced antibiotics.

Immuno-deficient patients no longer need to carry the heavy financial burden of other treatment options (i.e. antiviral cocktails and combo therapies) nor must they endure the toxic side effects and their associated additional costs. Transfer factors in treatment is non toxic and non-addictive regardless of dosage amounts.

In the past there has been concern about properly regulating dosages. Those concerns have likewise been put to rest with recent developments in therapy involving transfer factors. Based on the doctor's assessment a therapeutic or prophylactic regimen is established for the patient which is then easily and routinely monitored via appropriate interval testing (20).

The Future Is Bright

Many physicians and other medical experts are voicing the same conclusions about combating infectious diseases - conventional pharmacology is not winning the war. In fact it is estimated that by the year 2030 currently known drugs will be helpless in fighting bacterial infection (24).

Therein lies the critical importance of transfer factors. By elevating the body's own miraculous immune response to specific antigens patients and doctors alike can potentially reach their mutual goal which is effective treatment of the patient's viral illness and the hope of success.

Today people suffering from common bacterial infections are often administered antibiotics to augment the body's own reservoir of antibodies. The story changes however with serious virus infections such as Epstein-Barr virus cytomegalovirus cryptosporosis Hrpes simplex types 1 and 2 HIV and others. In such cases patients have literally been overwhelmed by invading antigens and have lost much of their body's miraculous ability to fight infection. What is required is an "outside source" that both possesses and can transmit the precise antigen-fighting ability necessary for the recipient to once again fight the viral infection on their own. Transfer factors have been intensely researched and documented since its discovery in 1949 by Dr HS Lawrence. Essentially transfer factors are an immunotherapy which transfers distinct cell-mediated immunity from an immuno-sufficient donor to a deficient recipient. Results of this treatment are consistent and remarkable for viral fungal and parasitic infections alike all without side effects and toxicity (6).